Table 1.
Characteristics of prescriptions including sodium hyaluronate eye drop over time.
| 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total prescriptions | 39,838 | 54,539 | 77,403 | 98,961 | 124,346 | 148,861 | 168,245 | 193,632 | 219,421 | 230,691 | 242,299 | 254,125 | 267,009 | 276,537 |
| Ophthalmology | 37,960 (95%) | 51,730 (95%) | 73,444 (95%) | 93,675 (95%) | 117,015 (94%) | 139,854 (94%) | 158,286 (94%) | 182,465 (94%) | 205,838 (94%) | 214,887 (93%) | 226,382 (93%) | 236,916 (93%) | 249,083 (93%) | 257,866 (93%) |
| Internal medicine | 1,022 (3%) | 1,218 (2%) | 1,945 (3%) | 2,626 (3%) | 3,731 (3%) | 4,624 (3%) | 5,110 (3%) | 5,827 (3%) | 7,171 (3%) | 8,217 (4%) | 8,246 (3%) | 9,134 (4%) | 9,495 (4%) | 10,168 (4%) |
| Others | 856 (2%) | 1,591 (3%) | 2,014 (3%) | 2,660 (3%) | 3,600 (3%) | 4,383 (3%) | 4,849 (3%) | 5,340 (3%) | 6,412 (3%) | 7,587 (3%) | 7,671 (3%) | 8,075 (3%) | 8,431 (3%) | 8,503 (3%) |
| Multi-use forms | 39,838 (100%) | 54,522 (100%) | 77,074 (100%) | 98,244 (99%) | 121,153 (97%) | 142,861 (96%) | 154,504 (92%) | 170,443 (88%) | 188,040 (86%) | 190,188 (82%) | 184,734 (76%) | 182,085 (72%) | 176,509 (66%) | 173,306 (63%) |
| Ophthalmology | 37,960 (95%) | 51,713 (95%) | 73,126 (95%) | 92,977 (95%) | 113,907 (94%) | 134,073 (94%) | 144,961 (94%) | 159,939 (94%) | 175,572 (93%) | 176,192 (93%) | 171,266 (93%) | 168,510 (93%) | 163,183 (92%) | 160,316 (93%) |
| Internal medicine | 1,022 (3%) | 1,218 (2%) | 1,940 (3%) | 2,616 (3%) | 3,679 (3%) | 4,543 (3%) | 4,907 (3%) | 5,466 (3%) | 6,620 (4%) | 7,420 (4%) | 7,092 (4%) | 7,159 (4%) | 6,962 (4%) | 7,138 (4%) |
| Others | 856 (2%) | 1,591 (3%) | 2,008 (3%) | 2,651 (3%) | 3,567 (3%) | 4,245 (3%) | 4,636 (3%) | 5,038 (3%) | 5,848 (3%) | 6,576 (3%) | 6,376 (3%) | 6,416 (4%) | 6,364 (4%) | 5,852 (3%) |
| Disposable forms | – | 17 (0%) | 329 (0%) | 717 (1%) | 3,193 (3%) | 6,000 (4%) | 13,741 (8%) | 23,189 (12%) | 31,381 (14%) | 40,503 (18%) | 57,565 (24%) | 72,040 (28%) | 90,500 (34%) | 103,231 (37%) |
| Ophthalmology | – | 17 (100%) | 318 (97%) | 698 (97%) | 3,108 (97%) | 5,781 (96%) | 13,325 (97%) | 22,526 (97%) | 30,266 (96%) | 38,695 (96%) | 55,116 (96%) | 68,406 (95%) | 85,900 (95%) | 97,550 (94%) |
| Internal medicine | – | – | 5 (2%) | 10 (1%) | 52 (2%) | 81 (1%) | 203 (1%) | 361 (2%) | 551 (2%) | 797 (2%) | 1,154 (2%) | 1,975 (3%) | 2,533 (3%) | 3,030 (3%) |
| Others | – | – | 6 (2%) | 9 (1%) | 33 (1%) | 138 (2%) | 213 (2%) | 302 (1%) | 564 (2%) | 1,011 (2%) | 1,295 (2%) | 1,659 (2%) | 2,067 (2%) | 2,651 (3%) |
| Expenditure (1,000 USD) | 143 | 190 | 289 | 397 | 552 | 708 | 870 | 1,068 | 1,329 | 1,528 | 1,617 | 1,918 | 2,278 | 2,593 |
| Multi-use forms | 143 (100%) | 190 (100%) | 284 (98%) | 382 (96%) | 495 (90%) | 600 (85%) | 661 (76%) | 733 (69%) | 844 (64%) | 872 (57%) | 758 (47%) | 795 (41%) | 848 (37%) | 897 (35%) |
| Disposable | – | – | 5 (2%) | 15 (4%) | 57 (10%) | 108 (10%) | 209 (24%) | 335 (31%) | 485 (36%) | 656 (43%) | 859 (53%) | 1,123 (59%) | 1,430 (63%) | 1,696 (65%) |
| Estimated market (million USD) | 7 | 10 | 14 | 20 | 28 | 35 | 44 | 53 | 66 | 76 | 81 | 96 | 114 | 130 |
| Total benefits provided by the NHI (million USD) | 11,391 | 12,523 | 13,691 | 15,304 | 17,865 | 20,479 | 21,983 | 24,973 | 28,163 | 30,046 | 31,111 | 33,218 | 35,487 | 38,108 |
| Percent of estimated market | 0.06% | 0.08% | 0.11% | 0.13% | 0.15% | 0.17% | 0.20% | 0.21% | 0.24% | 0.25% | 0.26% | 0.29% | 0.32% | 0.34% |
Total prescriptions are composed of multi-use and disposable forms.
Given the sample size (2% of the total population) of the NHIS-NSC, estimated market size was calculated.
Percent of estimated market was calculated using estimated market and total benefits provided by the NHI (HIRA, 2020).
United States Dollar to South Korean Won exchange rate was assumed to be 1,200.
Results were rounded.